Public Employees Retirement Association of Colorado Sells 929 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Public Employees Retirement Association of Colorado lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,082 shares of the biotechnology company’s stock after selling 929 shares during the period. Public Employees Retirement Association of Colorado’s holdings in BioMarin Pharmaceutical were worth $1,841,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC boosted its stake in BioMarin Pharmaceutical by 259.8% during the fourth quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after buying an additional 278 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in BioMarin Pharmaceutical by 135.3% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock worth $42,000 after buying an additional 249 shares during the period. Jones Financial Companies Lllp purchased a new position in BioMarin Pharmaceutical during the fourth quarter worth $43,000. First Horizon Advisors Inc. boosted its stake in BioMarin Pharmaceutical by 33.3% during the fourth quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock worth $56,000 after buying an additional 144 shares during the period. Finally, Allworth Financial LP boosted its stake in BioMarin Pharmaceutical by 54.9% during the fourth quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock worth $58,000 after buying an additional 214 shares during the period. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $84.07 on Tuesday. BioMarin Pharmaceutical Inc. has a twelve month low of $73.68 and a twelve month high of $99.56. The company’s 50 day moving average is $81.89 and its 200 day moving average is $85.31. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12. The company has a market cap of $15.96 billion, a PE ratio of 78.57, a price-to-earnings-growth ratio of 1.20 and a beta of 0.32.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of BioMarin Pharmaceutical from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, June 27th. Robert W. Baird lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $104.00 to $72.00 in a research note on Friday, May 17th. Morgan Stanley lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating for the company in a research note on Friday, April 26th. Scotiabank boosted their target price on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research note on Thursday, April 25th. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $89.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, July 25th. Nine investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $102.00.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,850 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the sale, the executive vice president now owns 56,157 shares in the company, valued at approximately $4,773,906.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Brian Mueller sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $75.19, for a total transaction of $375,950.00. Following the transaction, the chief financial officer now owns 72,159 shares in the company, valued at approximately $5,425,635.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Eric Davis sold 1,850 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total value of $157,268.50. Following the transaction, the executive vice president now owns 56,157 shares in the company, valued at approximately $4,773,906.57. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,700 shares of company stock worth $5,209,352. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.